Clinical trial updates for CTCL: ARGX-110 and mogamulizumab

Martine Bagot, MD, PhD, of the Saint Louis Hospital, Paris, France, discusses two clinical trials for cutaneous T-cell lymphoma (CTCL): the Phase I/II study (NCT01813539) assessing the role of ARGX-110, a CD70-directed monoclonal antibody, and the Phase III MAVORIC study (NCT01728805) examining the effect of mogamulizumab. Prof. Bagot speaks at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, on the safety, efficacy and tolerability of these treatments.